Silence Therapeutics PLC (SLN) — Cash Flow Reinvestment Rate

Latest as of June 2021: 0.02x

Silence Therapeutics PLC (SLN) has a Cash Flow Reinvestment Rate of 0.02x as of June 2021, reinvesting $440.00K (capex $439.00K plus investments $1.00K) from operating cash flow of $26.03 Million. Explore reinvestment intensity of Silence Therapeutics PLC to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.02x
(Capex + Investments) / Operating CF

Total Reinvested

$440.00K
Capex + Investments

Operating Cash Flow

$26.03 Million
USD

Capital Expenditures

$439.00K
USD

Silence Therapeutics PLC Cash Flow Reinvestment Rate (2019–2021)

Historical reinvestment intensity for Silence Therapeutics PLC across 2 annual periods. Also explore SLN total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Silence Therapeutics PLC (2019–2021)

Year-by-year capital reinvestment analysis for Silence Therapeutics PLC. For live market cap and broader valuation context, see SLN stock market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2021 1.28x $11.80 Million $9.19 Million $1.80 Million ▼ -85.2%
2019 8.70x $15.02 Million $1.73 Million $9.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow